Trial Profile

Conditions for Prescribing Liraglutide in Medical Practice and Assessment of Maintenance Level, Tolerability, and Efficacy of Victoza (Liraglutide) in Subjects With Type 2 Diabetes.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 31 Jan 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Liraglutide (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms EVIDENCE
Sponsors Novo Nordisk

Most Recent Events

30 Jan 2017 Results of subgroup analysis (patients from primary care physician and specialist care settings) published in the Advances in Therapy
30 Sep 2015 Results published in the Advances in Therapy.
19 Sep 2014 Results of post-hoc analysis of effectiveness of switching from a DPP-4 inhibitor (DPP-4i) to liraglutide presented at 50th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com